Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study
Timely germline testing at BC diagnosis might increase CRRM rates in BRCApv carriers, thereby improving survival.
Authors
- Inge Søkilde Pedersen (ORCID: https://orcid.org/0000-0002-9902-8040)
- Maj‐Britt Jensen (ORCID: https://orcid.org/0000-0001-5348-3040)
- A. Kostov (ORCID: https://orcid.org/0009-0008-5034-8597)
- Bent Ejlertsen (ORCID: https://orcid.org/0000-0001-8761-714X)
- Maria Rossing (ORCID: https://orcid.org/0000-0003-4325-3027)
- Luis C. Berrocal-Almanza (ORCID: https://orcid.org/0000-0003-1634-9971)
- Anne‐Vibeke Lænkholm (ORCID: https://orcid.org/0000-0003-2166-8686)
- Annabeth Høgh Petersen (ORCID: https://orcid.org/0000-0002-4503-6942)
- Karin Wadt (ORCID: https://orcid.org/0000-0003-2882-6798)
- Lise Lotte Christensen (ORCID: https://orcid.org/0000-0001-5622-3068)
- Miguel Miranda
- Mads Thomassen (ORCID: https://orcid.org/0000-0003-0078-1217)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
- Vejle Sygehus (DK)
- Region of Southern Denmark (DK)
- Danish Breast Cancer Cooperative Group (DK)
- Aalborg University (DK)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1007/s10549-025-07726-2
- Citations
- 2
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.63